Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

BACKGROUND: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demon...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Moon, Jai-Hee, Hong, Seung-Woo, Kim, Jeong Eun, Shin, Jae-Sik, Kim, Jin-Sun, Jung, Soo-A, Ha, Seung Hee, Lee, Seul, Kim, Joseph, Lee, Dae Hee, Park, Yoon Sun, Kim, Dong Min, Park, Sang-Soo, Hong, Jun Ki, Kim, Do Yeon, Kim, Eun Ho, Jung, Joonyee, Kim, Mi Jin, Kim, Seung-Mi, Deming, Dustin A., Kim, Kyunggon, Kim, Tae Won, Jin, Dong-Hoon
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734664/
https://ncbi.nlm.nih.gov/pubmed/30944457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0434-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi